Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
Volume2.00
Average Volume (3M)24.92K
Market Cap
$1.88M
Enterprise Value$1.06
Total Cash (Recent Filing)$12.00K
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding50,297,450
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Liposomal Delivery Tech (DNAbilize)A proprietary liposomal delivery platform addresses a durable industry barrier for RNAi therapeutics: safe, targeted intracellular delivery. This technological moat can increase probability of clinical success, enable licensing or partnerships, and sustain competitive differentiation over multiple development cycles.
Focused Oncology Pipeline (AML, Targeted Agents)Concentrated expertise in hematologic malignancies and targeted mechanisms (Grb2, Bcl-2) creates clear scientific focus, operational priorities, and potential for expedited regulatory paths in oncology. A disciplined pipeline focus can improve trial design and partnership appeal over the medium term.
Lower 2025 Cash Burn And Low Absolute DebtOperating and free cash outflow fell materially in 2025 (~$1.6M vs ~$10.6M prior) while total debt remained under $0.5M, reducing near-term interest/refinancing pressure. Combined, these trends lengthen runway and lower immediate financing urgency, improving survivability through upcoming milestones.
Bears Say
Negative Stockholders' Equity And Asset DepletionA negative equity position and sharply reduced asset base materially weaken financial flexibility and creditworthiness. This structural balance-sheet deterioration increases the probability of dilutive financing, restricts strategic options, and raises execution risk for multi-stage clinical programs.
No Revenue Across Multiple YearsAbsent any commercial revenue over several years, the company remains fully dependent on successful clinical outcomes and external funding. Lack of product sales means no proven commercial model or margin sustainability, extending time to self-funded operations and increasing binary clinical risk.
Ongoing Negative Cash Flow And Funding RelianceChronic negative operating and free cash flow forces repeated capital raises, creating dilution and execution uncertainty. Even with 2025 improvement, persistent reliance on external financing is a structural vulnerability that can delay programs or alter strategic priorities if funding terms deteriorate.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.14 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $1.88M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 5 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on May 08, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Technical Analysis
Matinas BioPharma
―
Cellectar Biosciences
―
Moleculin Biotech
―
Nucana
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors